The effect of intravesical bacillus Calmette-Guerin therapy on the upper urinary tract

E. Mukamel, E. Vilkovsky, H. Hadar, D. Engelstein, B. Nussbaum, C. Servadio

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

A total of 66 patients with low grade, low stage transitional cell carcinoma of the bladder who were treated with intravesical bacillus Calmette-Guerin (BCG) underwent cystourethrography to detect vesicoureteral reflux. BCG was instilled weekly for 6 weeks and monthly thereafter for up to 24 months. Whenever vesicoureteral reflux was found or morphological abnormalities were detected on excretory urography (IVP) an isotope renal scan was performed to evaluate the relative renal function. Vesicoureteral reflux was found in 13 patients (19.7%): 10 had grades 1 and 2A, and 3 had grade 2B reflux. The number of BCG instillations ranged from 8 to 22. IVPs were normal in 11 patients. In 2 patients mild unilateral dilatation was present before BCG instillations, and this remained unchanged during and after therapy. None of the 13 patients with vesicoureteral reflux had IVP features suggestive of urinary tuberculosis. In 11 patients the refluxing renal systems had normal relative renal function (50 to 55%). Two patients had a decrease to 40% of the relative renal function with normal IVPs, suggesting a nonBCG related cause. We conclude that BCG therapy is safe in patients with minimal reflux.

Original languageEnglish
Pages (from-to)980-981
Number of pages2
JournalJournal of Urology
Volume146
Issue number4
DOIs
StatePublished - Oct 1991
Externally publishedYes

Keywords

  • BCG vaccine
  • Bladder neoplasms
  • Carcinoma, transitional cell
  • Vesico-ureteral reflux

Fingerprint

Dive into the research topics of 'The effect of intravesical bacillus Calmette-Guerin therapy on the upper urinary tract'. Together they form a unique fingerprint.

Cite this